Cencora Executive Explains How DSCSA Compliance Investments Can Generate Shared Value Across Supply Chain Partners
Cencora's Gregg Gorniak discusses DSCSA compliance investments, emphasizing the need for shared value among supply chain partners. He highlights operational improvements from bundling, but notes adoption depends on mutual economic benefits. Gorniak argues compliance investments must deliver returns across partnerships to drive innovation. His session at HDA’s 2026 Traceability Seminar will outline a framework for strategic growth through compliance.
How this was made
The 30-second read
Why it matters
Exec commentary suggests operational savings but no immediate financial impact.
Market read
Provides insight into compliance‑driven efficiency strategies for pharma supply chains, with modest relevance to traders.
What to watch
Potential regulatory changes or future mandates could alter the economics of bundling.
Background
The DSCSA (Drug Supply Chain Security Act) requires serialization at the unit level; the article explores optional bundling beyond the law.
Market effects
May influence other pharma distributors and manufacturers to consider bundled serialization for efficiency.
Primarily U.S. pharmaceutical supply chain; limited global ripple.
Low, as compliance standards are U.S.-specific.
Counterpoint
Without clear cost‑benefit data, firms may view bundled serialization as an unnecessary expense.
Key entities
- CompanyCencora Inc.
U.S. pharmaceutical wholesale and distribution company.
- ExecutiveGregg Gorniak
Vice President of manufacturer operations and data services at Cencora.
